FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Inclusion Criteria: * Men and women ≥18 years * Newly diagnosed with histologically confirmed stage II-Ill colon cancer * Completed curative-intent surgical resection * Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil \[5-FU\] / leucovorin \[LV\], capecitabine, FOLFOX \[5-FU, LV, oxaliplatin\], CAPOX \[capecitabine and oxaliplatin\] * Patients must have started chemotherapy or plan to start with receipt of the first exercise visit by 3rd infusion visit. Patients enrolled at the Dana-Farber Cancer Institute and who are receiving FOLFOX chemotherapy are eligible to enroll in the pharmacokinetics sub-study. * No planned major surgery anticipated in the intervention period * Sufficient time to heal from any major surgery to start of intervention, including colostomy reversal (port-a-cath removal excluded) * Approval by either oncologist or surgeon to participate in trial * Readiness as determined by the Physical Activity Readiness Questionnaire * Ability to understand and the willingness to sign a written informed consent document in English * Willingness to be randomized Exclusion Criteria: * Concurrent actively treated other cancer (except non-melanoma skin cancer, in situ cervical cancer or localized prostate cancer treated with surveillance only) * Patients with untreated hypertension (\>180 mm Hg systolic or \>100 mm Hg diastolic) appearing in the patient's medical record in the two weeks prior to screening * Presence of metastatic disease * Current strength training \>2x week for the past 3 or more months * Patients enrolled in other clinical trials of weight loss, physical activity or dietary interventions are ineligible.